TNNI3K could be a novel molecular target for the treatment of cardiac diseases

Recent Patents on Cardiovascular Drug Discovery

Volumn 4, Issue 3, 2009, Pages 203-210

  Lai, Zhong Fang ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cardiac ankyrin repeats; Cardiac contraction; Cardiac hypertrophy; Cardiac troponin I; Diagnosis agents; Ischemia injury; Molecular therapeutics; Myocardial infarction; TNNI3K

Indexed keywords

ANKYRIN; CARDIOTONIC AGENT; DIGITALIS; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXIREDOXIN 3; PROTEIN TNN13K; STRESS ACTIVATED PROTEIN KINASE; TROPONIN I; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; BINDING SITE; DIGITALIS INTOXICATION; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; HEART DISEASE; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC HEART DISEASE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; STEM CELL TRANSPLANTATION;

EID: 76149135724     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489009789152285     Document Type: Review

References (25)

1. Yorinaka, H., Ding, J.F., Meng, X.M.: WO2006057278 (2006).
2. Yorinaka, H., Ding, J.F., Meng, X.M.: EP1832299 (2007).
3. Yorinaka, H., Ding, J.F., Meng, X.M.: US20090022692 (2009).
4. Zhao Y, Meng XM, Wei YJ, et al. Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin I. J Mol Med 2003; 81: 297-304.
5. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934.
6. Wang H, Chen C, Song X, et al. MEF2C is an essential regulatory element required for unique expression of the cardiac-specific CARK gene. J Cell Mol Med 2008; 12: 304-315.
7. Feng Y, Cao HQ, Liu Z, Ding JF, Meng XM. Identification of the dual specificity and the functional domains of the cardiac - specific protein kinase TNNI3K. Gen Phys B 2007; 26: 104-109.
8. Feng Y, Liu DQ, Wang Z, et al. AOP-1 interacts with cardiacspecific protein kinase TNNI3K and down-regulates its kinase activity. Biochemistry (Mosc) 2007; 72: 1199-1204.
9. Lai ZF, Chen YZ, Feng LP, et al. Overexpression of TNNI3K, a cardiac-specific MAP kinase, promotes P19CL6-derived cardiac myogenesis and prevents myocardial infarction-induced injury. Am J Physiol Heart Circ Physiol 2008; 295: H708-716.
10. Kuratomi S, Ohmori Y, Ito M, et al. The cardiac pacemakerspecific channel Hcn4 is a direct transcriptional target of MEF2. Cardiovasc Res 2009; 83(4): 682-687.
11. Bennett V, Baines AJ. Spectrin and ankyrin-based pathways: Metazoan inventions for integrating cells into tissues. Physiol Rev 2001; 81: 1353-1392.
12. Mohler PJ, Schott JJ, Gramolini AO, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421: 634-639.
13. Luft FC. Hearts of this ILK rely on TNNI3K, a MAPKKK that regulated TNNI3. J Mol Med 2003; 81: 279-280.
14. Li P, Meng XM, Lai ZF, et al. Suppression of multiple pathwaymediated apoptosis is involved in protective effects of TNNI3K on hypoxia-induced injury in rat neonatal cardiomyocytes. Cardiovasc Res 2009: [Unpublished].
15. Miller MK, Bang ML, Witt CC, et al. The muscle ankyrin repeat proteins: CARP, ankrd2/Arpp and DARP as a family of titin filament-based stress response molecules. J Mol Biol 2003; 333: 951-964.
16. Wang XJ, Yang X, Chen JZ, et al. TNNI3K, a cardiac-specific kinase, promotes cardiac hypertrophy in vivo. (AHA Meeting Abstracts). Circulation 2006; 114 (Suppl): II-5.
17. Wang HM, Gao MM, Xiao B, et al. Investigation on mutation of cardiac troponin I-interacting kinase TNNI3K gene in patients with cardiac hypertrophy. Chin J Cardiovasc Dis (in Chinese) 2004; 32: 741-742.
18. Clerk A, Sugden PH. Untangling the Web: Specific signaling from PKC isoforms to MAPK cascades. Cir Res 2001; 89: 847-849.
19. Luedde M, Katus HA, Frey N. Novel molecular targets in the treatment of cardiac hypertrophy. Recent Pat Cardiovasc Drug Discov 2006; 1: 1-20.
20. Schenttler, R.A., Jones Jr., W.D., Claxton, G.P.: US4670450 (1985).
21. Norton, T.R., Shibata, S., Kashiwagi, M.: US4059694 (1977).
22. Norton, T.R., Shibata, S., Kashiwagi, M.: US4166113 (1979).
23. Hess, G., Hess, A.: US20080081344 (2008).
24. Hallermayer, K., Katus, H., Kaya, Z.: US20070172888 (2007).
25. Jin, J.-P.: US20080032929 (2008).